Ignite Creation Date:
2024-10-26 @ 3:40 PM
Last Modification Date:
2024-10-26 @ 3:40 PM
Study NCT ID:
NCT06597565
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-09-12
Brief Title:
A Phase II Study of ACR-368 and Low Dose Gemcitabine in RM HNSCC
Sponsor:
None
Organization:
None
Study Overview
Official Title:
A Phase II Study of ACR-368 and Low Dose Gemcitabine Combination Therapy in Patients With Recurrent andor Metastatic Head and Neck Squamous Cell Carcinoma
Status:
RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of the study is to determine the activity and safety of ACR-368 prexasertib in combination with gemcitabine in participants with Head and Neck Squamous Cell Carcinoma HNSCC Participants will receive the study drugs ACR-368 and a low dose of gemcitabine once every 2 weeks in 4-week cycles and will continue on treatment unless the disease deteriorates
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None